“Whole plant extracted, biosynthesized and synthetic cannabinoids all hold therapeutic promise for given indications and intended uses,” said Rob Davidson, chief executive officer and chairman of CURE Pharmaceutical. “At CURE, we focus on synthetic cannabinoids for CUREfilm products, but with our new licensing business model, we will expand the impact and applications of our technology to these other promising approaches by partnering with an industry leader in this market.”
CURE will enable the manufacturing of CUREfilms that deliver cannabis extracts, expanding the commercialization and monetization of CUREfilm technology. CURE retains the right to manufacture synthetic cannabinoids for pharmaceutical applications.
The CUREfilm license gives Canopy Growth a dosage form that is ideal for the delivery of cannabinoids. It offers increased bioavailability, ease and precision of dosing and greater palatability. Cannabinoids are chemical compounds found in plants, such as cannabis (phytocannabinoids), synthesized by cells of the human body (endocannabinoids) or synthesized in a laboratory (biosynthetic cannabinoids) that interact with the body’s endocannabinoid system. The endocannabinoid system is recognized as an important modulatory system in the function of the brain, endocrine and immune tissues.
This is the first time CURE’s products have been manufactured outside of their Oxnard-based facility. Canopy Growth has the capacity to mass produce CUREfilms with cannabis extracts in its 5.6 million square feet facility, expanding the commercialization and monetization of CUREfilm technology. The CUREfilm license gives Canopy a dosage form that is ideal for the delivery of cannabinoids. It offers increased bioavailability, ease and precision of dosing and palatability.